跳至主要内容
临床试验/NCT07372495
NCT07372495招募中不适用

Cervical Cerclage Plus Vaginal Progesterone Versus Vaginal Progesterone Alone in Twin Pregnancies With a Short Cervix for Prevention of Preterm Birth: a Randomized Controlled Trial

National Hospital of Obstetrics and Gynecology6 个研究点 分布在 1 个国家目标入组 260 人开始时间: 2026年4月10日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
260
试验地点
6
主要终点
Preterm birth < 28 weeks

研究概览

简要总结

This study aims to compare the effectiveness of cervical cerclage combined with progesterone versus progesterone alone in preventing preterm birth among women with twin pregnancies and a short cervix (cervical length ≤ 30 mm). Participants will be randomly allocated to either the intervention group (cerclage plus progesterone) or the control group (progesterone alone).

详细描述

The incidence of multiple pregnancies has increased rapidly over the years mainly due to the resultant widespread use of assisted reproduction techniques. The twin birth rate in the USA has risen 70%, from 19 per 1000 live births in 1980 to 31 per 1000 live births in 2020. Twin pregnancies have a high risk on preterm birth (PTB) which is associated with increased risk of neonatal mortality and long-term morbidity. Around 60% of twin pregnancies deliver prior to 37 weeks and 12% before 34 weeks of gestation, with rates 5 and 8 times higher than the equivalent rates for a singleton pregnancy, respectively. Children born at an early gestational age are at increased risk of short-term morbidities affecting vital organ systems such as lungs, brain, bowels and are at increased risk of severe infection and sepsis. Perinatal mortality is strongly associated with extreme PTB. Survivors are at increased risk for developmental and behavioral disorders. In Vietnam, the rate of twin pregnancies deliver at < 28 weeks was about 11% in 2019. Caring for extremely premature infants is a significant burden for families and society. Therefore, obstetricians have a need for high-quality evidence for effective treatments.

Cervical length measurement (ideally transvaginal) is the preferred method of screening for preterm birth in twins; 25mm is a pragmatic cut-off between 18 and 24 gestational weeks (Grade of recommendation: C). Majority of the studies conducted previously has taken the cut-off cervical length as ≤ 25 mm. A systematic review and meta-analysis (13 retrospective studies and 3 RCTs) showed that cervical cerclage may reduce preterm birth in twin pregnancies with a cervical length <25 mm; however, preterm birth before 37, 34, and 28 weeks remained high (56.7%, 38.8%, and 11.7%, respectively)5, compared with much lower rates in singleton pregnancies (6.2%, 4.7%, and 0.4%). These findings support the need for further studies on preterm birth prevention in twin pregnancies with a cervical length >25 mm. In 2025, Yen et al. showed that cervical cerclage was more effective than pessary in twin pregnancies with a cervical length ≤28 mm, particularly in reducing preterm birth <28 weeks, with benefit observed at 25-28 mm. However, preterm birth rates remained high, suggesting that intervention at a higher cervical length threshold may be justified. Given gestational age-related cervical shortening and the substantially higher preterm birth risk in twins, a higher threshold corresponding to the 10th percentile (≤30 mm) has been proposed. Accordingly, we selected ≤30 mm as the intervention threshold in twin pregnancies.

In singleton pregnancies, vaginal progesterone is recommended as the primary intervention for pregnant women with a cervical length less than 25mm with consistently demonstrated effectiveness in preventing premature labor. In cases with a prior spontaneous preterm delivery and a short cervix, the placement of a vaginal cerclage should be considered. Conversely, there is less evidence on the optimal strategy for preventing PTB in twin pregnancies. In twins, IM 17- OHPC and cervical pessary are not indicated in order to prevent PTB. Evidence regarding the effectiveness of vaginal progesterone and cerclage remains unclear. Several randomized trials and systematic reviews reported little or no benefit of cerclage in twin pregnancies. However, these studies were limited by small sample size and large heterogeneity in their inclusion criteria, study populations, and outcomes observed. The data are insufficient to recommend for or against these interventions in the clinical circumstances. Moreover, in the a last few years, an increasing number of studies reporting a potential beneficial role of cerclage in reducing the risk of PTB and adverse outcomes in twin pregnancies have been published. The latest ISUOG practice guidelines (2025) stated that a combined strategy of physical-exam-indicated cerclage, antibiotics, and tocolytics may be considered in asymptomatic twin pregnancy with dilated cervix before 24 weeks of gestation and a cervical cerclage may be considered when the cervical length is ≤ 15 mm before 24 weeks of gestation (grade of recommendation: C). However, these findings are mainly based on observational studies and require confirmation in large and adequately powered RCTs.

In conclusion, there is a lack of well-designed RCT's on the effect of vaginal cerclage in asymptomatic twin pregnancies. We propose a multi-center randomized trial on the effectiveness of vaginal cerclage in women with a twin pregnancy and a short cervix (less than 30mm) in the second trimester with relevant outcomes assessing not only PTB at different cut-offs but also adverse maternal and neonatal outcomes.

This open label, multi-center, randomized controlled trial aims to compare the effectiveness of cervical cerclage combined with progesterone versus progesterone alone in preventing preterm birth among women with twin pregnancies with a cervix ≤ 30 mm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

盲法说明

Participants and investigators will not be blinded for the intervention.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Maternal age ≥ 18
  • Twin pregnancy
  • Asymptomatic short cervix (CL≤30mm) at routine ultrasound investigation
  • Gestational age at 16+0- 24+0 weeks

排除标准

  • A potential paticipant who meets any of the following criteria will be excluded from participation in this trial:
  • Women with twin pregnancy in which one or both fetuses are diagnosed with a major structural or congenital abnormality that is likely to influence the composite adverse neonatal outcome.
  • Women with a monochorionic monoamniotic twin pregnancy
  • A monochorionic twin pregnancy with twin-to-twin transfusion syndrome before or at the time of inclusion.
  • Patients have indications for vaginal cerclage: Recurrent late miscarriage (from 14 weeks) or preterm birth occurring two or more times.
  • Women with dilatation of the cervix diagnosed by ultrasound or physical exam
  • Women with overt symptoms of preterm labor at the time of measurement of the short cervix (regular contractions, PPROM, recurrent blood loss).
  • Women with the presence of fever ≥ 38 degrees Celsius.
  • Women with a placenta previa, vasa previa.
  • Uterine malformations: unicornuate uterus, bicornuate uterus, uterine septum, fibroid…
  • Severe maternal conditions (heart failure, chronic kidney disease, systemic lupus erythematosus …)

研究组 & 干预措施

Cerclage plus progesterone

Experimental

Participants will receive cervical cerclage according to local protocols within one week after randomization. The procedure will be performed by three senior clinicians experienced in cerclage, using the McDonald technique. In addition, vaginal micronized progesterone will be administered at a total daily dose of 400 mg, given as Utrogestan® 200 mg (Besins Healthcare, France) twice daily, in the morning and at bedtime. Participants will be asked to record their vaginal progesterone application in a patient diary sheet for up to 140 days.

干预措施: Cervical cerclage (Procedure)

Cerclage plus progesterone

Experimental

Participants will receive cervical cerclage according to local protocols within one week after randomization. The procedure will be performed by three senior clinicians experienced in cerclage, using the McDonald technique. In addition, vaginal micronized progesterone will be administered at a total daily dose of 400 mg, given as Utrogestan® 200 mg (Besins Healthcare, France) twice daily, in the morning and at bedtime. Participants will be asked to record their vaginal progesterone application in a patient diary sheet for up to 140 days.

干预措施: Progesterone (Drug)

Progesterone alone

Active Comparator

Vaginal micronized progesterone will be administered at a total daily dose of 400 mg, given as Utrogestan® 200 mg (Besins Healthcare, France) twice daily, in the morning and at bedtime. Participants will be asked to record their vaginal progesterone application in a patient diary sheet for up to 140 days

干预措施: Progesterone (Drug)

结局指标

主要结局

Preterm birth < 28 weeks

时间窗: From randomization until 27 6/7 weeks

Number of participants with preterm birth before 28 weeks of gestation

次要结局

  • Gestational age at birth(At birth)
  • Preterm birth < 32 weeks(From randomization until 31 6/7 weeks)
  • Preterm birth < 34 weeks(From randomization until 33 6/7 weeks)
  • Preterm birth < 37 weeks(From randomization until 36 6/7 weeks)
  • Spontaneous preterm birth <28 weeks(From randomization until 27 6/7 weeks)
  • Spontaneous preterm birth < 32 weeks(From randomization until 31 6/7 weeks)
  • Spontaneous preterm birth < 34 weeks(From randomization until 33 6/7 weeks)
  • Spontaneous preterm birth < 37 weeks(From randomization until 36 6/7 weeks)
  • Iatrogenic preterm birth < 28 weeks(From randomization until 27 6/7 weeks)
  • Iatrogenic preterm birth < 32 weeks(From randomization until 31 6/7 weeks)
  • Iatrogenic preterm birth < 34 weeks(From randomization until 33 6/7 weeks)
  • Iatrogenic preterm birth < 37 weeks(From randomization until 36 6/7 weeks)
  • Preterm premature rupture of membranes(From randomization until delivery, assessed up to 37 weeks of gestation)
  • Hospital costs(From randomization to the time of hospital discharge of both the mother and the neonate(s), assessed up to 90 days after delivery)
  • Maternal death(From randomization until maternal hospital discharge, assessed up to 28 days after delivery)
  • Composite of maternal adverse outcome(From randomization until maternal hospital discharge, assessed up to assessed up to 28 days after delivery)
  • Apgar score at 1 minute(Assessed at 1 minute after birth)
  • Apgar score at 5 minutes(Assessed at 5 minutes after birth)
  • Apgar Score < 7 at 5 minutes(Assessed at 5 minutes after birth)
  • Birthweight(At birth)
  • Number of neonates in need for respiratory supports(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Length of ventilation(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Respiratory distress syndrome(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Admission to the neonatal intensive care unit(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Length of neonatal intensive care unit stay(From admission to Neonatal Intensive Care Unit until neonatal hospital discharge or hospital referral, assessed up to 3 months corrected age)
  • Length of neonatal admission(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Neonatal infection(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Neonatal seizures(From delivery to neonatal hospital discharge, assessed up to 3 months corrected age)
  • Intra-ventricular hemorrhage grades III and IV(From delivery until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Necrotizing enterocolitis (NEC)(From birth until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Neonatal sepsis(From birth until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Neonatal referred hospital transfer for severe morbidities(From birth until referral to another neonatal hospital, assessed up to 3 months corrected age)
  • Stillbirth(From randomization until delivery, assessed up to assessed up to 28 days after delivery)
  • Neonatal deaths(From birth until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Composite neonatal adverse outcome(From birth until neonatal hospital discharge, assessed up to 3 months corrected age)
  • Maternal side effects(From randomization until delivery, assessed up to 28 days after delivery)
  • Number of admission episodes for threatened preterm birth(From randomization until delivery, assessed up to 28 days after delivery)

研究者

发起方
National Hospital of Obstetrics and Gynecology
申办方类型
Other
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验